Division of Pediatric Allergy, Immunology, & Bone Marrow Transplant, Benioff Children's Hospital, University of California San Francisco, San Francisco, CA, USA.
Division of Hematology/Immunology, Department of Pediatrics, Alberta Children's Hospital, University of Calgary, Calgary, AB, Canada.
J Clin Immunol. 2021 Jan;41(1):38-50. doi: 10.1007/s10875-020-00865-9. Epub 2020 Oct 2.
The Primary Immune Deficiency Treatment Consortium (PIDTC) enrolled children with severe combined immunodeficiency (SCID) in a prospective natural history study of hematopoietic stem cell transplant (HSCT) outcomes over the last decade. Despite newborn screening (NBS) for SCID, infections occurred prior to HSCT. This study's objectives were to define the types and timing of infection prior to HSCT in patients diagnosed via NBS or by family history (FH) and to understand the breadth of strategies employed at PIDTC centers for infection prevention.
We analyzed retrospective data on infections and pre-transplant management in patients with SCID diagnosed by NBS and/or FH and treated with HSCT between 2010 and 2014. PIDTC centers were surveyed in 2018 to understand their practices and protocols for pre-HSCT management.
Infections were more common in patients diagnosed via NBS (55%) versus those diagnosed via FH (19%) (p = 0.012). Outpatient versus inpatient management did not impact infections (47% vs 35%, respectively; p = 0.423). There was no consensus among PIDTC survey respondents as to the best setting (inpatient vs outpatient) for pre-HSCT management. While isolation practices varied, immunoglobulin replacement and antimicrobial prophylaxis were more uniformly implemented.
Infants with SCID diagnosed due to FH had lower rates of infection and proceeded to HSCT more quickly than did those diagnosed via NBS. Pre-HSCT management practices were highly variable between centers, although uses of prophylaxis and immunoglobulin support were more consistent. This study demonstrates a critical need for development of evidence-based guidelines for the pre-HSCT management of infants with SCID following an abnormal NBS.
NCT01186913.
原发性免疫缺陷治疗联盟 (PIDTC) 在过去十年中对患有严重联合免疫缺陷症 (SCID) 的儿童进行了前瞻性的造血干细胞移植 (HSCT) 结果的自然史研究。尽管进行了新生儿筛查 (NBS) 以筛查 SCID,但仍在 HSCT 之前发生了感染。本研究的目的是定义通过 NBS 或家族史 (FH) 诊断的患者在 HSCT 前感染的类型和时间,并了解 PIDTC 中心在感染预防方面采用的策略范围。
我们分析了 2010 年至 2014 年间通过 NBS 和/或 FH 诊断为 SCID 并接受 HSCT 治疗的患者的感染和移植前管理的回顾性数据。2018 年对 PIDTC 中心进行了调查,以了解他们在 HSCT 前管理方面的实践和方案。
通过 NBS 诊断的患者 (55%) 比通过 FH 诊断的患者 (19%) 更常见感染 (p=0.012)。门诊与住院管理对感染无影响 (分别为 47%和 35%;p=0.423)。PIDTC 调查受访者对于 HSCT 前管理的最佳环境 (门诊或住院) 没有达成共识。虽然隔离实践有所不同,但免疫球蛋白替代和抗菌预防更为普遍。
由于 FH 而诊断为 SCID 的婴儿感染率较低,且比通过 NBS 诊断的婴儿更快地进行 HSCT。尽管预防和免疫球蛋白支持的使用更为一致,但各中心的 HSCT 前管理实践差异很大。本研究表明,迫切需要制定基于证据的指南,以指导 NBS 异常后的 SCID 婴儿进行 HSCT 前的管理。
NCT01186913。